Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab.

Autor: Phillips T; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI. Electronic address: tphillips@coh.org., Lugtenburg P; On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Kalsekar A; Genmab, Plainsboro, NJ., Mutebi A; Genmab, Plainsboro, NJ., Wang A; AbbVie, North Chicago, IL., Blaedel J; Genmab, Plainsboro, NJ., Kosa K; RTI Health Solutions, Ann Arbor, MI., Martin S; RTI Health Solutions, Ann Arbor, MI., Sacchi M; Genmab, Plainsboro, NJ., Kilavuz N; Genmab, Plainsboro, NJ., Thieblemont C; Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-Oncologie, Université de Paris, Paris, France.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Mar; Vol. 24 (3), pp. e78-e87.e2. Date of Electronic Publication: 2023 Nov 27.

PCR20 Improvements in Symptoms, Impact of Treatment, and Satisfaction with Treatment Among Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Treated with Subcutaneous Epcoritamab

Autor: Kosa, K., Mutebi, A., Wang, A., Blaedel, J., Sacchi, M., Martin, S.

Publikováno v: In Value in Health June 2023 26(6) Supplement:S315-S315

Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma

Autor: Siegel, D.S. Dimopoulos, M.A. Ludwig, H. Facon, T. Goldschmidt, H. Jakubowiak, A. San-Miguel, J. Obreja, M. Blaedel, J. Stewart, A.K.

Purpose: In the ASPIRE study of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide plus dexamethasone (Rd) in patients with relapsed or refractory multiple myeloma, progression-free survival was significantly improved in the carfi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::ac00ef79b60b6287e49bec903cd4122e
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3085534

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

REAL‐WORLD OUTCOMES WITH NOVEL THERAPIES IN R/R DLBCL.

Autor: Crombie, J., Jun, M., Wang, T., Mutebi, A., Wang, A., Chibber, A., Kamalakar, R., Ukropec, J., Blaedel, J., Kalsekar, A.

Publikováno v: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p719-720, 2p